The pharmaceutical industry is uneven: some pharmaceutical companies expect their performance to double, while others expect a decline of 780%

 

Among them, Lianhuan Pharmaceutical stated that according to preliminary calculations by the finance department, it is expected that the company's net profit attributable to 2025 will be negative, and there will be a loss in operating performance in 2025. Dongya Pharmaceutical stated that according to preliminary calculations by the company's finance department, it is expected that the net profit attributable to the company in 2025 will be negative, and the operating performance in 2025 will incur losses. Jinyu Medical announced that it is expected that the net profit attributable to shareholders of the listed company will be negative in 2025, and the company's operating performance will suffer losses in 2025, mainly due to the prolonged collection period of some accounts receivable, resulting in significant credit impairment losses.
 

And Zhifei Biotechnology is expected to lose over 10 billion yuan. According to the 2025 performance forecast released by Zhifei Biotechnology, Zhifei Biotechnology expects a net profit loss attributable to its parent company of 10.698 billion yuan to 13.726 billion yuan in 2025, a year-on-year decrease of 630% to 780%, and a profit of 2.018 billion yuan in the same period last year; It is expected that the non deductible net profit loss will be 10.554 billion yuan to 13.541 billion yuan, a year-on-year decrease of 630% to 780%, with a profit of 1.991 billion yuan in the same period last year.
 

It is reported that this is the first time Zhifei Biotechnology has suffered an annual loss since its listing in 2010. Its expected loss in performance may be related to factors such as lower than expected sales in the main product market, as well as high accounts receivable and inventory. According to the company's performance forecast, Zhifei Biotechnology has made provisions for impairment of inventory due to changes in market demand, near expiry date, and expiry date, resulting in its net realizable value being lower than the book value of inventory; Evaluate the expected credit loss of accounts receivable and provide credit impairment losses based on their aging status.
 

However, standing at a new starting point at the beginning of the 15th Five Year Plan, personnel from Zhifei Biotechnology stated that the company will adhere to innovation driven development, continue to break through the comfort zone of homogeneous competition, shift towards systematic innovation guided by clinical value and public health needs, and strive to achieve breakthroughs. It is reported that in recent years, many key research projects of enterprises have been accelerated, and preventive vaccines and therapeutic biologics have been developed simultaneously, providing more diverse solutions for disease prevention and clinical treatment.
 

In addition, Weili Medical expects a net profit attributable to the owners of the parent company of 75 million to 95 million yuan in 2025, a year-on-year decrease of 57% -66%. The net profit after deducting non recurring gains and losses was 65 million to 85 million yuan, a year-on-year decrease of 60% -69%. The main factors contributing to the decline in performance are the slowdown in demand in the company's wolf and medical markets, as well as intensified industry competition, resulting in a decline in operating performance. Based on this, the company has provisioned a goodwill impairment of approximately 147 million yuan.
 

Hengdi Pharmaceutical expects a net profit attributable to shareholders of the listed company of 31 million to 39 million yuan in 2025, a year-on-year decrease of 66.14% to 57.40%. After deducting non recurring gains and losses, the net profit will be 5.5 million to 8.2 million yuan, a year-on-year decrease of 92.46% to 88.76%. The decline in performance is mainly due to the main product ibuprofenAPI (Active Pharmaceutical Ingredient)The competition in the market for some specialty active pharmaceutical products has intensified, resulting in a decrease in gross profit margin and a reduction in cash management interest income due to the decrease in interest rates.
 

Yiping is expected to incur a net profit loss of 313 million to 442 million yuan in 2025, compared to a loss of 540 million yuan in the same period last year. During the reporting period, there was a certain degree of decline in the company's product sales and gross profit margin. In addition, the use of the company's Guangdong Ruishi Innovative API Production Base led to an increase in depreciation and amortization, as well as continuous investment in research and development, which affected the company's operating performance.
 

The analysis points out that the performance differentiation of pharmaceutical companies this time is essentially the result of the transformation period of the pharmaceutical industry. At present, the pharmaceutical industry is in a critical stage of strict compliance supervision, deepening medical insurance cost control, and increasing innovation requirements. The pharmaceutical industry may accelerate its reshuffle. In the wave of industry transformation, adhering to the original intention of innovation and building a solid compliance bottom line are necessary for enterprises to stand firm in differentiation and adjustment, injecting momentum into the long-term development of the pharmaceutical industry.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone.